29975-16-4

Basic information

• Product Name: Estazolam
• Synonyms: 2,4)triazolo(4,3-a)(1,4)-benzodiazepine,8-chloro-6-phenyl-4h-(;3-a)(1,4)benzodiazepine,8-chloro-6-phenyl-4h-s-triazolo(;4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-6-phenyl-;4H-s-Triazolo(4,3-a)(1,4)benzodiazepine, 8-chloro-6-phenyl-;8-Chloro-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine;abbott47631;Abbott-47631;Alprazolam M (hydroxy-)-CH2O
• CAS NO: 29975-16-4
• Molecular Formula: C₁₆H₁₁ClN₄
• Molecular Weight: 294.74
• EINECS: 249-982-4
• Product Categories: Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 29975-16-4.mol
• Article Data: 7

Chemical Properties

• Melting Point: 228-229°
• Boiling Point: 448.04°C (rough estimate)
• Flash Point: 11 °C
• Appearance: /
• Density: 1.2294 (rough estimate)
• Vapor Pressure: 9.55E-10mmHg at 25°C
• Refractive Index: 1.6110 (estimate)
• Storage Temp.: 2-8°C
• PKA: pKa 2.84(H2O) (Uncertain)
• CAS DataBase Reference: Estazolam(CAS DataBase Reference)
• NIST Chemistry Reference: Estazolam(29975-16-4)
• EPA Substance Registry System: Estazolam(29975-16-4)

Safety Data

• Hazard Codes: Xi,T,F
• Statements: 36/37/38-39/23/24/25-23/24/25-11
• Safety Statements: 36/37/39-45-36/37-16-7
• RIDADR: 3249
• WGK Germany: 3
• RTECS: XZ5473500
• HazardClass: 6.1(b)
• PackingGroup: III
• Hazardous Substances Data: 29975-16-4(Hazardous Substances Data)

Usage

Description

Estazolam, sold under the brand name Prosom among others, is a tranquilizer medication of the triazolobenzodiazepine (TBZD) class, which are benzodiazepines (BZDs) fused with a triazole ring . It possesses anxiolytic, anticonvulsant, hypnotic, sedative and skeletal muscle relaxant properties.

Pharmacology

Estazolam is classed as a "triazolo" benzodiazepine drug.Estazolam exerts its therapeutic effects via its benzodiazepines receptor agonist properties.Estazolam at high doses decreases histamine turnover via its action at the benzodiazepine-GABA receptor complex in mouse brains.

Adverse reactions

Common adverse reactions such as drowsiness, drowsiness, dizziness, fatigue, unsteady gait, etc., increasing the dose may occasionally cause adverse reactions such as headache, ataxia, motor dysfunction, slurred speech, respiratory depression, tremor, etc.?Long-term use can lead to memory loss Adverse reactions such as decline, weight gain, cognitive impairment, loss of libido, etc. In addition, long-term use of estazolam can cause down-regulation of benzodiazepine receptors in the central nervous system, which can lead to tolerance and dependence, and sudden withdrawal can cause Headache, insomnia, depression, nervousness, restlessness, irritability, anxiety, tremor, tachycardia and other withdrawal symptoms, namely drug addiction, are the most serious adverse reactions of long-term use of estazolam.

Originator

Eurodin,Takeda,Japan,1975

Uses

A benzodiazepine derivative possessing anxiolytic, anticonvulsant, and muscle relaxant properties. It is commonly prescribed to treat short-term insomnia. Controlled Substance.

Definition

ChEBI: A triazolo[4,3-a][1,4]benzodiazepine having a phenyl group at position 6 and a chloro substituent at position 8. A short-acting benzodiazepine with general properties similar to diazepam, it is given by mouth as a hypnotic in the short-term ma agement of insomnia.

Manufacturing Process

A mixture of 5.74 grams (0.020 mol) of 7-chloro-1,3-dihydro-5-phenyl-2H- 1,4-benzodiazepine-2-thione, 3.6 grams (0.060 mol) of formic acid hydrazide and 200 ml of 1-butanol was refluxed for 3.75 hours with a slow stream of nitrogen bubbling through the mixture. The mixture was concentrated, the residue was suspended in water and the suspension was filtered. The filter cake consisted principally of unchanged starting material. The filtrate was concentrated, ethyl acetate and Skellysolve B hexanes being added during the concentration, giving crude product (2.54 grams), MP 220.5° to 225°C. Recrystallization of this material from ethyl acetate-Skellysolve B hexanes gave 8-chloro-6-phenyl-4H-s-triazolo[4,3-a] [1,4]benzodiazepine, MP 228° to 229°C.

Brand name

Prosom (Abbott).

Therapeutic Function

Hypnotic, Sedative

InChI:InChI=1/C16H11ClN4/c17-12-6-7-14-13(8-12)16(11-4-2-1-3-5-11)18-9-15-20-19-10-21(14)15/h1-8,10H,9H2

Upstream product

• 55514-31-3 2-methylimidazolium chloride 
• 122-51-0 orthoformic acid triethyl ester 
• 7564-07-0 2-amino-7-chloro-5-phenyl-3H-1,4-benzodiazepine 
• 18091-89-9 7-chloro-2-hydrazino-5-phenyl-3H-1,4-benzodiazepine 
• 693-98-1 2-methylimidazole 
• 6313-33-3 formamidine hydrochloride 

Downstream Products

• 71616-85-8 8-chloro-1,4-bis-(dimethylamino-methyl)-6-phenyl-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine 
• 37115-32-5 adinazolam 
• 121899-04-5 4-<(dimethylamino)methyl>-8-chloro-6-phenyl-4H-s-triazolo<4,3-a><1,4>-benzodiazepine hydrochloride 
• 39667-62-4 1-bromo-8-chloro-6-phenyl-1H-s-triazolo<4,3-a><1,4>benzodiazepine 
• 118790-80-0 [2-(3-Aminomethyl-[1,2,4]triazol-4-yl)-5-chloro-phenyl]-phenyl-methanone 
• 56910-08-8 8-chloro-1-(4-methylpiperazino)-6-phenyl-4H-s-triazolo<4,3-a>-1,4-benzodiazepine 
• 88701-67-1 8-chloro-1-<4-(2-methoxyethyl)piperazino>-6-phenyl-4H-s-triazolo<4,3-a>-1,4-benzodiazepine 
• 37115-43-8 8-chloro-1-hydroxymethyl-6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine 

Relevant articles and documents

5-chloro-2-(3-chloromethyl-S-triazolyl)benzophenone chloroacetate as well as crystal form and preparation method thereof

The invention discloses 5-chloro-2-(3-chloromethyl-S-triazolyl) benzophenone chloroacetate as well as a crystal form and a preparation method thereof. The preparation method comprises the following steps: dissolving 5-chloro-2-((N-chloracetyl-N-chloracetylhydrazinemethyl)amino)benzophenone in a solvent, adding chloroacetic acid, stirring and heating the mixed liquid to carry out rearrangement reaction, cooling and crystallizing the reaction product after the reaction is finished, carrying out solid-liquid separation, and drying the substance to obtain a chloroacetate crystal form of 5-chloro-2-(3-chloromethyl-S-triazolyl)benzophenone, namely a crystal form A. According to the invention, based on the of the 5-chloro-2-(3-chloromethyl-S-triazolyl) benzophenone chloroacetate, the requirementfor subsequent synthesis of eszolam can be met, chloroacetic acid is used for rearrangement and salification in the preparation process, and complex solvent conversion aftertreatment operation is avoided.

Quinazolines and 1,4-benzodiazepines. 81. s-Triazolo[4,3-a][1,4]benzodiazepines by oxidative cyclization of hydrazones

-

Animal feed and process

An animal feed comprising a compound of the group consisting of 6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepines of the formula: STR1 WHEREIN R is selected from the group consisting of hydrogen, alkyl of 1 to 3 carbon atoms, inclusive, phenyl, benzyl and -COOR' in which R' is alkyl of 1 to 4 carbon atoms, inclusive; wherein R1 is selected from the group consisting of hydrogen and alkyl of 1 to 3 carbon atoms, inclusive; and wherein R2, R3, R4 and R5 are selected from the group consisting of hydrogen, alkyl of 1 to 3 carbon atoms, inclusive, halogen, nitro, cyano, trifluoromethyl, and alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkanoylamino and dialkylamino in which the carbon chain moieties are of 1 to 3 carbon atom, inclusive and their pharmacologically acceptable acid addition salts in combination with a nutrient feed. A process for obtaining increased productivity in meat producing, milk producing, and egg laying animals by feeding the aforementioned compounds in combination with nutrient feeds.